Sugi Predict

Sugi Predict / Compounds / SCHEMBL1770655

SCHEMBL1770655

SCHEMBL1770655

COc1cccc(OCCBr)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.61
▸ MAOB P27338 6/20 0.55
▸ MTNR1A P48039 1/20 0.54
▸ MTNR1B P49286 1/20 0.54
▸ LMNA P02545 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ TSHR P16473 4/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ APP P05067 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30674601 1.00 MAPK1 (0.61) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL30674535 0.90 MAPK1 (0.59) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL3415011 0.90 MAPK1 (0.59) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL8155382 0.89 SMN1; SMN2 (0.50) MAPK1MAOBTSHRCYP1A2CYP3A4
SCHEMBL7389768 0.89 MAPK1 (0.57) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL1729519 0.87 MAPK1 (0.75) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL8552109 0.87 MAPK1 (0.56) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL29696901 0.87 MAPK1 (0.56) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL15923316 0.87 MAPK1 (0.56) MAPK1MAOBMTNR1AMTNR1BLMNA
SCHEMBL5281999 0.85 MAPK1 (0.57) MAPK1MTNR1AMTNR1BTSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117105872-A Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2023-11-24 — — CN claimed
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
CN-117105872-A Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2023-11-24 — — CN disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed
EP-0869792-A4 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 1999-09-22 — — EP disclosed
EP-0869792-A2 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-10-14 — — EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed
WO-1997023216-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 — — WO disclosed
EP-0445026-B1 Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them ADIR (FR) 1994-01-26 — — EP disclosed
US-5229399-A Analgesics ADIR ET COMPAGNIE (FR) 1993-07-20 — — US disclosed
US-5229398-A Analgesics ADIR ET COMPAGNIE (FR) 1993-07-20 — — US disclosed
US-5192775-A Analgesics ADIR ET COMPAGNIE (FR) 1993-03-09 — — US disclosed
EP-0445026-A1 Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1991-09-04 — — EP disclosed
EP-0252876-A1 Hydrogenated 1-phenoxyalkylpyridine-3-carboxylic-acid compounds CIBA-GEIGY AG (CH) 1988-01-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 MAPK1 1641/4885MAOB 331/4885MTNR1A 81/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 MAPK1 1641/4885MAOB 331/4885MTNR1A 81/4885
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 MAPK1 1641/4885MAOB 331/4885MTNR1A 81/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 MAPK1 1641/4885MAOB 331/4885MTNR1A 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.